Help
Hi everyone
Does anyone know anything about the methode of Dr. Stephen Davies for repairing chronic sci ??
Friendly regards
Page 1 of 1
Dr. Stephen Davies
Decorin and astrocytes
Rate Topic:
#1
- Newbie
-
- Group: Members
- Posts: 5
- Joined: 20-May 08
- Spinal Injury Level / Relationship:c6
Posted 28 April 2009 - 05:30 PM
#2
- The Boss!
-
- Group: Moderators
- Posts: 3,427
- Joined: 03-November 03
- Gender:Male
- Country:UK
- Spinal Injury Level / Relationship:C5/6 Anterior Cord
Posted 28 April 2009 - 05:50 PM
Hi,
This may be of interest to you:
Stephen Davies, Ph.D. Research Program
Dr. Stephen Davies, Ph.D., Associate Professor joined the department faculty in February of 2007. His research focuses on spinal cord regeneration. Dr. Davies describes his research as follows: When axons are severed by traumatic injury to the adult mammalian central nervous system, the surviving portion of an axon still connected to the cell body often sprouts but ultimately fails to regenerate across the site of injury back to its original target, resulting in a loss of nervous system function. Traumatic CNS injuries also result in the loss of glia vitally important for maintaining the structure and function of the nervous system. The brain and spinal cord often reacts to inflammation and the loss of glia at sites of injury by rapidly forming a fibrous meshwork of dense scar tissue directly in front of the cut ends of axons that are attempting to regenerate. Glial scar tissue is also rich in molecules such as chondroitin sulfate proteoglycans (CSPGs), semaphorins and ephrins that are known to be inhibitory to axon growth and thus CNS scar tissue presents a combined physical and molecular barrier to axon regeneration(1).
My research at UCDHSC is therefore focused on developing two, complementary approaches to repairing the injured adult CNS: 1.) suppression or removal of glial scar tissue to promote axon growth across sites of injury and 2.), development of neural precursor (stem cell-like) technologies to generate different types of central nervous system glia suitable for repairing the injured brain and spinal cord. My lab has shown that a naturally occurring antagonist of scar formation, a small leucine rich proteoglycan called decorin, is highly effective at suppressing inflammation, synthesis of CSPGs and fibrous scar formation when infused into acute spinal cord injuries in rats(2). More importantly decorin infusion permitted the rapid growth of axons across sites of injury in just 4 days. We are also interested in the ability of decorin to induce the expression of enzymes such as the serine protease plasmin in the injured CNS(3) that potentially have the ability to not only degrade scar tissue but promote plasticity of neural circuitry. In a parallel line of research, we have recently shown that a specific sub-type of astrocyte derived from embryonic glial restricted precursor cells (GRPs) can promote a high efficiency of axon regeneration and functional recovery after transplantation to adult spinal cord injuries(4). The use of GRP technology not only allows us to develop new cell types for repairing the adult CNS but also to investigate the basic glial cell biology of the normal and injured central nervous system.
Through gaining a greater understanding of the underlying molecular and cellular mechanisms that govern both failure and success of the adult CNS to regenerate our ultimate goal is to provide a clinically relevant strategy to promote efficient tissue repair and functional recovery of the injured human central nervous system.
His details can be found here: http://www.cuneurosurgery.com/team-profile...phen-davies.htm
Regards
Simon
This may be of interest to you:
Stephen Davies, Ph.D. Research Program
Dr. Stephen Davies, Ph.D., Associate Professor joined the department faculty in February of 2007. His research focuses on spinal cord regeneration. Dr. Davies describes his research as follows: When axons are severed by traumatic injury to the adult mammalian central nervous system, the surviving portion of an axon still connected to the cell body often sprouts but ultimately fails to regenerate across the site of injury back to its original target, resulting in a loss of nervous system function. Traumatic CNS injuries also result in the loss of glia vitally important for maintaining the structure and function of the nervous system. The brain and spinal cord often reacts to inflammation and the loss of glia at sites of injury by rapidly forming a fibrous meshwork of dense scar tissue directly in front of the cut ends of axons that are attempting to regenerate. Glial scar tissue is also rich in molecules such as chondroitin sulfate proteoglycans (CSPGs), semaphorins and ephrins that are known to be inhibitory to axon growth and thus CNS scar tissue presents a combined physical and molecular barrier to axon regeneration(1).
My research at UCDHSC is therefore focused on developing two, complementary approaches to repairing the injured adult CNS: 1.) suppression or removal of glial scar tissue to promote axon growth across sites of injury and 2.), development of neural precursor (stem cell-like) technologies to generate different types of central nervous system glia suitable for repairing the injured brain and spinal cord. My lab has shown that a naturally occurring antagonist of scar formation, a small leucine rich proteoglycan called decorin, is highly effective at suppressing inflammation, synthesis of CSPGs and fibrous scar formation when infused into acute spinal cord injuries in rats(2). More importantly decorin infusion permitted the rapid growth of axons across sites of injury in just 4 days. We are also interested in the ability of decorin to induce the expression of enzymes such as the serine protease plasmin in the injured CNS(3) that potentially have the ability to not only degrade scar tissue but promote plasticity of neural circuitry. In a parallel line of research, we have recently shown that a specific sub-type of astrocyte derived from embryonic glial restricted precursor cells (GRPs) can promote a high efficiency of axon regeneration and functional recovery after transplantation to adult spinal cord injuries(4). The use of GRP technology not only allows us to develop new cell types for repairing the adult CNS but also to investigate the basic glial cell biology of the normal and injured central nervous system.
Through gaining a greater understanding of the underlying molecular and cellular mechanisms that govern both failure and success of the adult CNS to regenerate our ultimate goal is to provide a clinically relevant strategy to promote efficient tissue repair and functional recovery of the injured human central nervous system.
His details can be found here: http://www.cuneurosurgery.com/team-profile...phen-davies.htm
Regards
Simon
Follow the Apparelyzed Forum on our Facebook and Twitter feeds.
#3
- Super Advanced
-
- Group: Members
- Posts: 7,196
- Joined: 05-October 08
- Gender:Male
- Country:Southern California, USA
- Spinal Injury Level / Relationship:C4/5/6 Incomplete
Posted 29 April 2009 - 06:34 AM
Simon,
Very interesting, although I don't understand the technical aspects, the direction this doctor's research is taking seems reasonable, I've always wondered what mechanisms were responsible for creating the scar tissue and the retarding of nerve re-connection/growth...very cool stuff. The link will be a definite read in the coming days.
Thanks for the info.
Jerry
Very interesting, although I don't understand the technical aspects, the direction this doctor's research is taking seems reasonable, I've always wondered what mechanisms were responsible for creating the scar tissue and the retarding of nerve re-connection/growth...very cool stuff. The link will be a definite read in the coming days.
Thanks for the info.
Jerry
Only after we have lost everything, are we free to do anything.
Shooting With Still Fingers - http://shootingwiths...s.blogspot.com/
Shooting With Still Fingers - http://shootingwiths...s.blogspot.com/
#4
- Newbie
-
- Group: Members
- Posts: 5
- Joined: 20-May 08
- Spinal Injury Level / Relationship:c6
Posted 29 April 2009 - 09:13 AM
Apparelyzed, on Apr 28 2009, 05:50 PM, said:
Hi,
This may be of interest to you:
Stephen Davies, Ph.D. Research Program
Dr. Stephen Davies, Ph.D., Associate Professor joined the department faculty in February of 2007. His research focuses on spinal cord regeneration. Dr. Davies describes his research as follows: When axons are severed by traumatic injury to the adult mammalian central nervous system, the surviving portion of an axon still connected to the cell body often sprouts but ultimately fails to regenerate across the site of injury back to its original target, resulting in a loss of nervous system function. Traumatic CNS injuries also result in the loss of glia vitally important for maintaining the structure and function of the nervous system. The brain and spinal cord often reacts to inflammation and the loss of glia at sites of injury by rapidly forming a fibrous meshwork of dense scar tissue directly in front of the cut ends of axons that are attempting to regenerate. Glial scar tissue is also rich in molecules such as chondroitin sulfate proteoglycans (CSPGs), semaphorins and ephrins that are known to be inhibitory to axon growth and thus CNS scar tissue presents a combined physical and molecular barrier to axon regeneration(1).
My research at UCDHSC is therefore focused on developing two, complementary approaches to repairing the injured adult CNS: 1.) suppression or removal of glial scar tissue to promote axon growth across sites of injury and 2.), development of neural precursor (stem cell-like) technologies to generate different types of central nervous system glia suitable for repairing the injured brain and spinal cord. My lab has shown that a naturally occurring antagonist of scar formation, a small leucine rich proteoglycan called decorin, is highly effective at suppressing inflammation, synthesis of CSPGs and fibrous scar formation when infused into acute spinal cord injuries in rats(2). More importantly decorin infusion permitted the rapid growth of axons across sites of injury in just 4 days. We are also interested in the ability of decorin to induce the expression of enzymes such as the serine protease plasmin in the injured CNS(3) that potentially have the ability to not only degrade scar tissue but promote plasticity of neural circuitry. In a parallel line of research, we have recently shown that a specific sub-type of astrocyte derived from embryonic glial restricted precursor cells (GRPs) can promote a high efficiency of axon regeneration and functional recovery after transplantation to adult spinal cord injuries(4). The use of GRP technology not only allows us to develop new cell types for repairing the adult CNS but also to investigate the basic glial cell biology of the normal and injured central nervous system.
Through gaining a greater understanding of the underlying molecular and cellular mechanisms that govern both failure and success of the adult CNS to regenerate our ultimate goal is to provide a clinically relevant strategy to promote efficient tissue repair and functional recovery of the injured human central nervous system.
His details can be found here: http://www.cuneurosurgery.com/team-profile...phen-davies.htm
Regards
Simon
This may be of interest to you:
Stephen Davies, Ph.D. Research Program
Dr. Stephen Davies, Ph.D., Associate Professor joined the department faculty in February of 2007. His research focuses on spinal cord regeneration. Dr. Davies describes his research as follows: When axons are severed by traumatic injury to the adult mammalian central nervous system, the surviving portion of an axon still connected to the cell body often sprouts but ultimately fails to regenerate across the site of injury back to its original target, resulting in a loss of nervous system function. Traumatic CNS injuries also result in the loss of glia vitally important for maintaining the structure and function of the nervous system. The brain and spinal cord often reacts to inflammation and the loss of glia at sites of injury by rapidly forming a fibrous meshwork of dense scar tissue directly in front of the cut ends of axons that are attempting to regenerate. Glial scar tissue is also rich in molecules such as chondroitin sulfate proteoglycans (CSPGs), semaphorins and ephrins that are known to be inhibitory to axon growth and thus CNS scar tissue presents a combined physical and molecular barrier to axon regeneration(1).
My research at UCDHSC is therefore focused on developing two, complementary approaches to repairing the injured adult CNS: 1.) suppression or removal of glial scar tissue to promote axon growth across sites of injury and 2.), development of neural precursor (stem cell-like) technologies to generate different types of central nervous system glia suitable for repairing the injured brain and spinal cord. My lab has shown that a naturally occurring antagonist of scar formation, a small leucine rich proteoglycan called decorin, is highly effective at suppressing inflammation, synthesis of CSPGs and fibrous scar formation when infused into acute spinal cord injuries in rats(2). More importantly decorin infusion permitted the rapid growth of axons across sites of injury in just 4 days. We are also interested in the ability of decorin to induce the expression of enzymes such as the serine protease plasmin in the injured CNS(3) that potentially have the ability to not only degrade scar tissue but promote plasticity of neural circuitry. In a parallel line of research, we have recently shown that a specific sub-type of astrocyte derived from embryonic glial restricted precursor cells (GRPs) can promote a high efficiency of axon regeneration and functional recovery after transplantation to adult spinal cord injuries(4). The use of GRP technology not only allows us to develop new cell types for repairing the adult CNS but also to investigate the basic glial cell biology of the normal and injured central nervous system.
Through gaining a greater understanding of the underlying molecular and cellular mechanisms that govern both failure and success of the adult CNS to regenerate our ultimate goal is to provide a clinically relevant strategy to promote efficient tissue repair and functional recovery of the injured human central nervous system.
His details can be found here: http://www.cuneurosurgery.com/team-profile...phen-davies.htm
Regards
Simon
Hi Simon
Thank you, its very interesting
regards
This post has been edited by maloel: 29 April 2009 - 09:15 AM
#5
- Newbie
-
- Group: Members
- Posts: 40
- Joined: 03-September 08
- Gender:Male
- Spinal Injury Level / Relationship:t6-t10
Posted 01 May 2009 - 09:42 PM
Apparelyzed, on Apr 28 2009, 06:50 PM, said:
Hi,this is all good dose any one know when he will be finished his work and we can see the results
This may be of interest to you:
Stephen Davies, Ph.D. Research Program
Dr. Stephen Davies, Ph.D., Associate Professor joined the department faculty in February of 2007. His research focuses on spinal cord regeneration. Dr. Davies describes his research as follows: When axons are severed by traumatic injury to the adult mammalian central nervous system, the surviving portion of an axon still connected to the cell body often sprouts but ultimately fails to regenerate across the site of injury back to its original target, resulting in a loss of nervous system function. Traumatic CNS injuries also result in the loss of glia vitally important for maintaining the structure and function of the nervous system. The brain and spinal cord often reacts to inflammation and the loss of glia at sites of injury by rapidly forming a fibrous meshwork of dense scar tissue directly in front of the cut ends of axons that are attempting to regenerate. Glial scar tissue is also rich in molecules such as chondroitin sulfate proteoglycans (CSPGs), semaphorins and ephrins that are known to be inhibitory to axon growth and thus CNS scar tissue presents a combined physical and molecular barrier to axon regeneration(1).
My research at UCDHSC is therefore focused on developing two, complementary approaches to repairing the injured adult CNS: 1.) suppression or removal of glial scar tissue to promote axon growth across sites of injury and 2.), development of neural precursor (stem cell-like) technologies to generate different types of central nervous system glia suitable for repairing the injured brain and spinal cord. My lab has shown that a naturally occurring antagonist of scar formation, a small leucine rich proteoglycan called decorin, is highly effective at suppressing inflammation, synthesis of CSPGs and fibrous scar formation when infused into acute spinal cord injuries in rats(2). More importantly decorin infusion permitted the rapid growth of axons across sites of injury in just 4 days. We are also interested in the ability of decorin to induce the expression of enzymes such as the serine protease plasmin in the injured CNS(3) that potentially have the ability to not only degrade scar tissue but promote plasticity of neural circuitry. In a parallel line of research, we have recently shown that a specific sub-type of astrocyte derived from embryonic glial restricted precursor cells (GRPs) can promote a high efficiency of axon regeneration and functional recovery after transplantation to adult spinal cord injuries(4). The use of GRP technology not only allows us to develop new cell types for repairing the adult CNS but also to investigate the basic glial cell biology of the normal and injured central nervous system.
Through gaining a greater understanding of the underlying molecular and cellular mechanisms that govern both failure and success of the adult CNS to regenerate our ultimate goal is to provide a clinically relevant strategy to promote efficient tissue repair and functional recovery of the injured human central nervous system.
His details can be found here: http://www.cuneurosurgery.com/team-profile...phen-davies.htm
Regards
Simon
This may be of interest to you:
Stephen Davies, Ph.D. Research Program
Dr. Stephen Davies, Ph.D., Associate Professor joined the department faculty in February of 2007. His research focuses on spinal cord regeneration. Dr. Davies describes his research as follows: When axons are severed by traumatic injury to the adult mammalian central nervous system, the surviving portion of an axon still connected to the cell body often sprouts but ultimately fails to regenerate across the site of injury back to its original target, resulting in a loss of nervous system function. Traumatic CNS injuries also result in the loss of glia vitally important for maintaining the structure and function of the nervous system. The brain and spinal cord often reacts to inflammation and the loss of glia at sites of injury by rapidly forming a fibrous meshwork of dense scar tissue directly in front of the cut ends of axons that are attempting to regenerate. Glial scar tissue is also rich in molecules such as chondroitin sulfate proteoglycans (CSPGs), semaphorins and ephrins that are known to be inhibitory to axon growth and thus CNS scar tissue presents a combined physical and molecular barrier to axon regeneration(1).
My research at UCDHSC is therefore focused on developing two, complementary approaches to repairing the injured adult CNS: 1.) suppression or removal of glial scar tissue to promote axon growth across sites of injury and 2.), development of neural precursor (stem cell-like) technologies to generate different types of central nervous system glia suitable for repairing the injured brain and spinal cord. My lab has shown that a naturally occurring antagonist of scar formation, a small leucine rich proteoglycan called decorin, is highly effective at suppressing inflammation, synthesis of CSPGs and fibrous scar formation when infused into acute spinal cord injuries in rats(2). More importantly decorin infusion permitted the rapid growth of axons across sites of injury in just 4 days. We are also interested in the ability of decorin to induce the expression of enzymes such as the serine protease plasmin in the injured CNS(3) that potentially have the ability to not only degrade scar tissue but promote plasticity of neural circuitry. In a parallel line of research, we have recently shown that a specific sub-type of astrocyte derived from embryonic glial restricted precursor cells (GRPs) can promote a high efficiency of axon regeneration and functional recovery after transplantation to adult spinal cord injuries(4). The use of GRP technology not only allows us to develop new cell types for repairing the adult CNS but also to investigate the basic glial cell biology of the normal and injured central nervous system.
Through gaining a greater understanding of the underlying molecular and cellular mechanisms that govern both failure and success of the adult CNS to regenerate our ultimate goal is to provide a clinically relevant strategy to promote efficient tissue repair and functional recovery of the injured human central nervous system.
His details can be found here: http://www.cuneurosurgery.com/team-profile...phen-davies.htm
Regards
Simon
This post has been edited by skeaman: 01 May 2009 - 09:43 PM
#6
- Member
-
- Group: Members
- Posts: 1,045
- Joined: 17-May 08
- Gender:Male
- Country:Denmark
- Spinal Injury Level / Relationship:C5/6 incomplete
Posted 01 May 2009 - 10:25 PM
I believe Dr. Davies is up to something for chronic injuries - so if you feel like making a difference - support the man.
http://www.cuneurosurgery.com/
I do, and I live on the other side of the planet, (that's why I don't think to hard on my chances to participate in clinical trials) but in the long 'run' - I hope...
http://www.cuneurosurgery.com/
I do, and I live on the other side of the planet, (that's why I don't think to hard on my chances to participate in clinical trials) but in the long 'run' - I hope...
Smile! See me:)
Share this topic:
Page 1 of 1